Elmiron Linked with Dangerous Vision Disorder:
In the last several months, mass tort litigation involving the Elmiron brand name medication has commenced in United States federal court. Before the dangers of taking Elmiron were fully understood, medical professionals prescribed Elmiron to patients to alleviate symptoms of interstitial cystitis, which is a painful bladder disorder. Elmiron is currently the only Food and Drug Administration (FDA) drug that can be taken orally to treat this disease. The following is a look at MDL 2973, the multi-district lawsuit that consolidated several cases against the company that sold Elmiron.
The Dangers of Taking Elmiron
Elmiron is manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. Following the FDA’s approval, Elmiron was introduced to the marketplace in 1996. Over two decades later, in 2018, reports began to connect Elmiron with retinal injuries. In cases in which a patient discontinues the use of the drug early enough, it is possible that retina damage will stop. However, patients who take Elmiron for an extended period of time commonly experience irreversible vision damage. The most common injury resulting from Elmiron use is retinal maculopathy, which is an ailment that damages the macula. Located in the center of the retina and found at the back of the eye, the macula is the location most sensitive to light and where vision is at its sharpest.
The harmful ingredient found in Elmiron is pentosan polysulfate sodium (PPS). Research has determined that PPS can cause a degenerative eye condition referred to as pigmentary maculopathy, which is one of the most common causes of blindness in the United States.
Over the last year, various lawsuits have begun to form against both distributors and manufacturers of Elmiron. The number of Elmiron lawsuits is expected to grow sharply due to the medication’s widespread availability and use as well as the fact that the FDA has not issued a recall for the drug.
The History of MDL 2973
Some of the most important events involved with MDL 2973 include:
- On December 15, 2020, the Judicial Panel on Multidistrict Litigation reviewed 63 Elmiron lawsuits filed in federal court and 65 potentially connected actions filed in other courts. The Panel consolidated these lawsuits into a New Jersey District Court to resolve all issues of discovery as well as other pre-trial matters. The plaintiffs in these lawsuits seek compensation for injuries they allege resulted from taking Elmiron.
- In June 2020, the FDA announced that labels on Elmiron must now display warnings about the dangers associated with its use.
- On March 10, 2021, the District of New Jersey issued a case management order stating that there were 196 product liability claims filed as part of MDL 2973.
- On April 14, 2021, an order was issued stating that the number of consolidated cases had grown to 209.
- On May 13, 2021, an order was issued stating that the cases had grown to 225.
Contact an Elmiron Lawyer at Cohen & Jaffe
If you or a loved one has taken Elmiron and are now suffering from associated damage, you should not hesitate to speak with an experienced attorney. Contact the Law Office of Cohen & Jaffe LLP today to schedule a free case evaluation with our personal injury lawyers.
For a free legal consultation, call 516-358-6900